The device is used to remove scar tissue from the left ventricle caused by a heart attack to allow the healthy part of the heart to function properly. It has implanted micro-anchors that are designed to bring the heart back to a more normal shape and size and minimize wall stress to boost blood flow across the body.
“Current methods for surgical remodelling of the ventricle are effective but highly invasive, and not well tolerated by patients. Having a less invasive method to treat the ventricle enables more patients to benefit from a more efficient heart.” Andrew Wechsler, MD, an emeritus professor at Drexel University told Medical Device Network.
Read the full article here.
Editor’s Note: This article was updated November 25, 2019 to clarify that BioVentrix did not secure FDA approval for its device.
More articles on supply chain:
Trump threatens to hike tariffs on China if deal not reached
10 hospitals seeking supply chain talent
FDA still allowing devicemakers to shield medical device safety flaws from the public
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
